Krishnansu S. Tewari, MD, discusses the excitement around immunotherapy in cervical cancer.
Krishnansu S. Tewari, MD, associate professor, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of California, Irvine, discusses the excitement around immunotherapy in cervical cancer.
Scientifically, it makes sense to look at these therapies in this setting, Tewari says. The mutational burden of cervical cancer is similar to other solid tumors where immunotherapy has had positive results, according to phase III findings.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More